Michael S Hofman (Michael Hofman)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 41

Top Topics

Radical Prostatectomy

Positron Emission Tomography

Top Venues

BJU international

Cancer imaging : the official publication of the International Cancer Imaging Society

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S Hofman
Comparison of quantitative whole body PET parameters on [ 68 Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 24 (1) (2024)
Kerry E Jewell, Michael S Hofman, Jeremy S L Ong, Sidney M Levy
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy. Radiology 311 (1) (2024)
Kerry E Jewell, Michael S Hofman, Jeremy S L Ong, Sidney M Levy
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy. Radiology 311 (1) (2024)
Kerry E Jewell, Michael S Hofman, Jeremy S L Ong, Sidney M Levy
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy. Radiology 311 (1) (2024)
Renu S Eapen, Scott G Williams, Sean Macdonald, Simon P Keam, Nathan Lawrentschuk, Lewis Au, Michael S Hofman, Declan G Murphy, Paul Joseph Neeson
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nature reviews. Urology (2024)
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S Hofman
Comparison of quantitative whole body PET parameters on [ 68 Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 24 (1) (2024)
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S Hofman
Comparison of quantitative whole body PET parameters on [ 68 Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 24 (1) (2024)
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S Hofman
Comparison of quantitative whole body PET parameters on [ 68 Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 24 (1) (2024)
Kerry E Jewell, Michael S Hofman, Jeremy S L Ong, Sidney M Levy
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy. Radiology 311 (1) (2024)
Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, Michael S Hofman, Louise Emmett, Jeremie Calais, Joseph R Osborne, Amir Iravani, Phillip Koo, Liza Lindenberg, Richard P Baum, Murat Fani Bozkurt, Roberto C Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney John Hicks, Thomas A Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M Mottaghy, Wim J G Oyen, Kambiz Rahbar, Heiko Schoder, Irene Virgolini, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Hermann
Joint EANM/SNMMI procedure guideline for the use of 177 Lu-labeled PSMA-targeted radioligand-therapy ( 177 Lu-PSMA-RLT). European journal of nuclear medicine and molecular imaging (2023)
Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong, Khaled Komrokji, Laura B Oswald, Heather S L Jim, Ghassan El-Haddad, Wolfgang Peter Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P Dicker, Jeremie Calais, Scott T Tagawa, Brian D Gonzalez
Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2023)
Louise Kostos, James P Buteau, Michael S Hofman, Arun A Azad
Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Therapeutic advances in medical oncology 15 (2023)
Matthew John Roberts, Ciara Conduit, Ian D Davis, Rachel M Effeney, Scott Williams, Jarad M Martin, Michael S Hofman, George Hruby, Renu Eapen, Christopher Gianacas, Nathan Papa, Richard De Abreu Lourenço, Haryana M Dhillon, Ray Allen, Antoinette Fontela, Baldeep Kaur, Louise Emmett, null null
DIPPER trial protocol: A multi-centre, randomised trial of salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy (ANZUP 2002). BJU international (2023)
Matthew John Roberts, George Hruby, Andrew Kneebone, Jarad M Martin, Scott G Williams, Mark Frydenberg, Declan G Murphy, Ben Namdarian, John W Yaxley, Michael S Hofman, Ian D Davis, Louise Emmett
Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU international (2023)
Siyu Huang, Sean Ong, Dean McKenzie, Adam Mirabelli, David C Chen, Thilakavathi Chengodu, Declan G Murphy, Michael S Hofman, Nathan Lawrentschuk, Marlon Lakmal Perera
Comparison of 18 F-based PSMA radiotracers with [ 68 Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate cancer and prostatic diseases (2023)
Duncan E K Sutherland, Raghava Kashyap, Price Jackson, James P Buteau, Declan G Murphy, Brian Kelly, Lavinia Spain, Shahneen Sandhu, Arun A Azad, Elizabeth Medhurst, Grace Kong, Michael S Hofman
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review. Therapeutic advances in medical oncology 15 (2023)
Robert Seifert, Sazan Rasul, Konstantin Seitzer, Maria Eveslage, Laya Rahbar Nikoukar, Katharina Kessel, Michael Schäfers, Josef Yu, Alexander R Haug, Marcus Hacker, Martin Boegemann, Lisa Bodei, Michael J Morris, Michael S Hofman, Kambiz Rahbar
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology (2023)
Paul Doan, William Counter, Nathan Papa, Gemma Sheehan-Dare, Bao Ho, Jonathan Lee, Victor Liu, James E Thompson, Shikha Agrawal, Matthew John Roberts, James Buteau, Michael S Hofman, Daniel A Moon, Nathan L Lawrentschuk, Declan G Murphy, Phillip D Stricker, Louise Emmett
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. BJU international (2022)
Mahasha P J Perera, Patrick B Thomas, Gail P Risbridger, Renea Taylor, Arun A Azad, Michael S Hofman, Elizabeth D Williams, Ian Vela
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers 14 (3) (2022)
Jonathan S O'Brien, Aoife McVey, Brian D Kelly, Pocharapong Jenjitranant, James Buteau, Michael S Hofman, Veeru Kasivisvanithan, Renu Eapen, Daniel Moon, Declan G Murphy, Nathan L Lawrentschuk
Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU international (2022)
Gideon Ptasznik, Nathan Papa, Brian D Kelly, James E Thompson, Phillip D Stricker, Matthew John Roberts, Michael S Hofman, James Buteau, Declan G Murphy, Louise Emmett, Daniel A Moon
High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU international (2022)
Ashwin Singh Parihar, Michael S Hofman, Amir Iravani
177 Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. Radiology (2022)
Adrian G Minson, Michael S Hofman, Michael J Dickinson
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. Leukemia & lymphoma 63 (1) (2021)
Courtney Lawhn Heath, Ali Salavati, Spencer C Behr, Steven P Rowe, Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, Louise Emmett, Michael S Hofman, Thomas A Hope
Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology 299 (2) (2021)
Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Sandhu, Ian D Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman, Arun A Azad
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU international 128 (3) (2021)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, Megan Crumbaker, Andrew Martin, Alison Y Zhang, Nisha Rana, Ailsa Langford, Jenna Mitchell, Sonia Yip, Roslyn Francis, Michael S Hofman, Shahneen Sandhu, Arun A Azad, Craig Gedye, Margaret McJannett, Martin R Stockler, Ian D Davis, null null
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU international 128 (5) (2021)
Shahneen Sandhu, Christina Guo, Michael S Hofman
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Michael S Hofman
Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Ramin Alipour, Nick Bucknell, Mathias Bressel, Sarah Everitt, Michael MacManus, Shankar Siva, Michael S Hofman, Tim Akhurst, Rodney J Hicks, Amir Iravani
Nodal metabolic tumour volume on baseline 18 F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy. Journal of medical imaging and radiation oncology 65 (6) (2021)
Andrei Gafita, Hui Wang, Andrew Robertson, Wesley Robert Armstrong, Raphael Zaum, Manuel Weber, Farid Yagubbayli, Clemens Kratochwil, Tristan R Grogan, Kathleen Nguyen, Fernando Navarro, Rouzbeh Esfandiari, Isabel Rauscher, Bjoern Menze, David Elashoff, Ebrahim S Delpassand, Ken Herrmann, Johannes Czernin, Michael S Hofman, Jeremie Calais, Wolfgang Peter Fendler, Matthias Eiber
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality? Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Nikhil Mayor, Niranjan Jude Sathianathen, James Buteau, Samantha Koschel, Marta Antón Juanilla, Jada Kapoor, Arun Azad, Michael S Hofman, Declan G Murphy
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU international 126 (5) (2020)
Arveen A Kalapara, Tatenda C Nzenza, Henry Y C Pan, Zita Ballok, Shakher Ramdave, Richard O'Sullivan, Andrew Ryan, Martin Cherk, Michael S Hofman, Badrinath R Konety, Nathan L Lawrentschuk, Damien Bolton, Declan G Murphy, Jeremy P Grummet, Mark Frydenberg
Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU international 126 (1) (2020)
James P Buteau, John F Seymour, Michael S Hofman
The evolving definition of bulky disease for lymphoma. Leukemia & lymphoma 61 (7) (2020)
Angelyn Anton, Olfat Kamel Hasan, Zita Ballok, Patrick Bowden, Anthony J Costello, Laurence Harewood, Niall M Corcoran, Phil Dundee, Justin S Peters, Nathan L Lawrentschuk, Andrew Troy, David Webb, Yee Chan, Andrew See, Shankar Siva, Declan G Murphy, Michael S Hofman, Ben Tran
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. BJU international 126 (4) (2020)
Pavel N Lobachevsky, Nicholas W Bucknell, Joel Mason, Diane Russo, Xiaoyu Yin, Lisa Selbie, David L Ball, Tomas Kron, Michael S Hofman, Shankar Siva, Olga A Martin
Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients. Cancers 12 (9) (2020)
Andrea K Miyahira, Kenneth J Pienta, John W Babich, Neil H Bander, Jeremie Calais, Peter Choyke, Michael S Hofman, Steven M Larson, Frank I Lin, Michael J Morris, Martin G Pomper, Shahneen Sandhu, Howard I Scher, Scott T Tagawa, Scott G Williams, Howard R Soule
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate 80 (15) (2020)
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European journal of nuclear medicine and molecular imaging 47 (10) (2020)
Amer Amin, Alexandar Blazevski, James E Thompson, Matthijs J V Scheltema, Michael S Hofman, Declan G Murphy, Nathan L Lawrentschuk, Niranjan Sathianathen, Jada Kapoor, Henry H Woo, Venu Chalasani, Krishan Rasiah, Pim J van Leeuwen, Reuben Tang, Thomas Cusick, Phillip D Stricker, Louise Emmett
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU international 125 (4) (2020)
Amir Iravani, John Violet, Arun Azad, Michael S Hofman
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate cancer and prostatic diseases 23 (1) (2019)
Michael S Hofman, Declan G Murphy, Scott G Williams, Tatenda C Nzenza, Alan Herschtal, Richard De Abreu Lourenco, Dale L Bailey, Ray Budd, Rodney J Hicks, Roslyn J Francis, Nathan L Lawrentschuk
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU international 122 (5) (2018)
Michael S Hofman, Rodney J Hicks
How We Read Oncologic FDG PET/CT. Cancer imaging : the official publication of the International Cancer Imaging Society 16 (1) (2016)